Extended Data Fig. 13: Clinical response of patients with lenvatinib-resistant advanced HCC to the combination of lenvatinib plus gefitinib. | Nature

Extended Data Fig. 13: Clinical response of patients with lenvatinib-resistant advanced HCC to the combination of lenvatinib plus gefitinib.

From: EGFR activation limits the response of liver cancer to lenvatinib

Extended Data Fig. 13

a, Schematic representation of the treatment timeline of patient A with HCC after diagnosis. The dates and treatments administered are annotated along the arrow. MRI scans of patient A were performed during lenvatinib monotherapy (IM-T1), after lenvatinib monotherapy (IM-T2) and after combination therapy (IM-T3). The red label indicates the duration of lenvatinib treatment; the green label indicates the duration of gefitinib treatment. b, Serum AFP level of patient A was monitored during lenvatinib monotherapy (AFP-T1), after lenvatinib monotherapy (AFP-T2), and after combination therapy of lenvatinib plus gefitinib (AFP-T3). c, Schematic representation of the treatment timeline of patient C with HCC after diagnosis. d, Serum AFP level of patient C during the indicated treatment. en, Serum AFP level of patients B, D–L was monitored before or during lenvatinib monotherapy (AFP-T1), after lenvatinib monotherapy (AFP-T2) and after combination therapy of lenvatinib plus gefitinib (AFP-T3). ox, MRI scans of patients with HCC were performed before or during lenvatinib monotherapy (IM-T1), after lenvatinib monotherapy (IM-T2) and after combination therapy of lenvatinib plus gefitinib (IM-T3). The tumour size of the major target lesions measured by MRI scan in patients with HCC was plotted on the y axes against indicated time point and treatment duration on the x axes

Source data.

Back to article page